Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (21540)	5/28/1998 9:42:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

Torben, I thought that you were supposed to be out the door, and on your way to the airport. << It was my understanding that if Panretin is approved for KS, all they have to do in order to advertise use for other indications is to ''show" that it is effective against those indications by publishing studies (2 papers or something like that). Seems it was pretty simple anyway. >> Thanks for the information. That could be an excellent next step for Panretin and skin cancer. But...... I wonder........ If Panretin is effective against AIDS KS, what are the odds that it would also be as effective against the other types of skin cancer? Good luck on your trip, Bob